Purchase of a modularized confocal microscope

用于下一代护理点免疫检测的光流控纳米等离子生物传感器 摘要：建立免疫预测模型需要全面了解免疫的复杂性和 免疫系统的动态功能行为。对这样的理解的需要是显而易见的，有许多 免疫相关疾病，目前尚无可行的治疗方法。细胞因子已被充分研究 由免疫细胞分泌的蛋白质，对细胞间信号调节成熟、生长、 以及特定细胞群体的反应能力。先前的研究表明，基于细胞因子的量化 免疫指纹提供了与传染病相关的临床和免疫学有用信息， 癌症、自身免疫性疾病和过敏移植。基础生物学领域正在进行的革命， 免疫学和临床发现关键取决于能够分散的诊断工具的可用性 护理点测量，以提供床边或 诊所。目前的临床技术主要是基于酶联免疫吸附试验(ELISA)。 复杂的标记和洗涤过程需要总的分析时间长达几个小时和 每个患者每次检测0.1-2毫升的样本量，这极大地阻碍了其在免疫监测中的应用 关爱的重点。因此，出现了对能够执行多项功能的变革性平台的新兴临床需求。 参量型细胞因子检测在了解患者动态免疫反应中的应用 准确的举止。这需要收集可能在几秒钟量级上用于离子传输的时间序列数据， 到小时，用于蛋白质水平的变化，以及到天，用于寄主体内具有传感器敏感性的表型变化 用最小样本量从生物相关浓度到单分子水平。要解决这个问题 需要，这项Mira应用的中心目标是开发集成的光流控纳米等离子体 用于快速、高通量、灵敏和多种细胞因子检测的生物传感平台 单细胞水平转向下一代护理点免疫分析。国际和平研究所提出了以下三项建议 项目：1)用于实时免疫的无标记、超灵敏、高通量的纳米血浆血清免疫分析 监测；2)个性化的多参数细胞功能免疫表型分析 免疫调节疗法；3)直接显示单细胞细胞因子分泌的纳米浆标尺和 细胞间通讯。计划中的多尺度研究将在实验和理论上架起桥梁 对免疫系统基本认识的差距，提高免疫系统的适用性、诊断和预测能力 治疗免疫系统疾病的力量。拟议的平台最终将使生物学家和临床医生 能够实时监控患者的免疫状态，这是一项变革性的成就，具有 对基础研究和临床应用的巨大影响。

Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-care Immunoassays Abstract: Building predictive models of immunity requires comprehensive understanding of the complex and dynamic functional behavior of immune system. A need for such understanding is obvious with a number of immune related diseases for which viable treatments are not currently available. Cytokines are well-studied proteins secreted by immune cells and essential for intercellular signaling to regulate the maturation, growth, and responsiveness of particular cell populations. Previous studies suggest that quantification of cytokine-based immune fingerprints provides clinically and immunologically useful information related to infectious diseases, cancer, autoimmune diseases, and allergy transplantation. The ongoing revolution in fundamental biology, immunology and clinical discovery critically hinges on the availability of diagnostic tools capable of decentralized point-of-care measurements to provide immediate quantitative information of cytokine levels at the bedside or in the clinic. Current existing clinical technology is mainly based on Enzyme-linked immunosorbent assay (ELISA). The complex labelling and washing processes require a total assay time up to more than a few hours and a sample volume of 0.1- 2 mL per test per patient, which greatly hinders its application for immune monitoring at the point of care. Thus, there is an emerging clinical demand for transformative platforms that can perform multi- parametric cytokine detection to understand the dynamical immune response of the patient in a rapid and accurate manner. This requires collecting time series data that could be on the order of seconds for ion transport, to hours for changes in protein levels, and to days for phenotypic changes in host body with sensor sensitivity from biological relevant concentration to single molecular level using minimum sample volume. To address this need, the central objectives of this MIRA application are to develop integrated optofluidic nanoplasmonic biosensing platforms for rapid, high throughput, sensitive and multiplex cytokine detection from whole blood to single-cell level towards next-generation point-of-care immunoassays. The PI proposes the following three projects: 1) Label free, ultra-sensitive, high throughput nanoplasmonic serum immunoassay for real-time immune monitoring; 2) Multi-parametric cellular functional immunophenotyping assay for personalized immunomodulatory therapy; 3) Nanoplasmon ruler for direct visualization of single-cell cytokine secretion and cell-to-cell communication. The planned multi-scale research both experimentally and theoretically will bridge the gap in fundamental understanding of immune system and enhance the applicability, diagnosis and prediction power for immune system diseases. The proposed platforms would ultimately gear the biologists and clinicians with capability to real-time monitor the immune status in patients, a transformative achievement that has enormous implications to fundamental research and clinical applications.